Anti-LAG3-ab

Drug Name

Anti-LAG3-ab

Classification

Monoclonal antibody

Development Status

Preclinical

Overview

Due to the important role of lymphocyte-associated gene 3 (LAG-3) in modulating T cell expansion and function, Anti-LAG3-ab enables T cells to regain cytotoxicity, thus enhancing the tumor killing effect by blockade of LAG-3. It also reduces the function of regulating T cells (Treg) to suppress the immune response.

In the studies, Anti-LAG3-ab showed the characteristics of high specificity and enhancing anti-tumor immunity. Combination Anti-LAG3-ab and anti-PD-1 immune check inhibitors showed exciting efficacy in fighting
PD-1 resistance.

Target

LAG-3 (CD223) is a type I transmembrane protein expressed mainly on activated T cells as well as natural killer cells, and consists of four extracellular immunoglobulin (Ig)-like domains (D1–D4). Similar to CD4, LAG-3 binds to major histocompatibility complex-II (MHC-II) on antigen presenting cells (APCs), but with 100 times stronger affinity.

LAG-3 suppresses T cells activation and cytokines secretion, thereby ensuring immune homeostasis. It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses.

Indication

Anti-LAG3-ab is being developed for use alone, or in combination with other checkpoint immunosuppressants, in the treatment of cancer patients with overexpression of LAG-3.